A Phase 2 interventional study of AC607 and Vehicle Only in Acute Kidney Injury, sponsored by AlloCure Inc.. Terminated at 31 sites in 2 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2014-08-06.
Sponsored by AlloCure Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.
Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 77th largest by enrollment of the 237 interventional ones that give a count, is one of 8 that started in 2012, is one of 54 in phase 2, and was the 72nd registered.
1,691 studies on the registry are indexed under Acute Kidney Injury; 393 are open to participants now.
Browse Acute Kidney Injury studies →72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 30–75
Massachusetts General Hospital · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
Bassett Healthcare · Sites in United States
Ages 18+
Dana Fuhrman · Sites in United States
Ages up to 18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 230 Acute Kidney Injury studies recruiting now, 162 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
370 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 69 · Phase 3 29 · Phase 4 23
First in 1999; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 156 is above the median of 100 across 817 interventional studies indexed under Acute Kidney Injury.
Median enrollment 67 across the 237 interventional studies, 124 across the 131 observational. Of the 240 that completed or were terminated, 84 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 370 have an industry lead sponsor. The 10 most frequent:
AlloCure Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
AlloCure Inc. has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
33 of the studies in Acute Kidney Injury with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161843Phase 3Ebima Clifford OkundayeUse of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF) | 2026-12-30 |
| NCT05399537Phase 3Vantive Health LLCSafety Evaluation of Prismocitrate 18 in Patients Receiving CRRT | 2027-01 |
| NCT05084196Phase 3Rutgers, The State University of New JerseyMelatonin for Prevention of Kidney Injury | 2027-06-01 |
| NCT07001098Stanford UniversityAmino Acids for Cardiac Surgery Associated AKI | 2026-11 |
| NCT07016074University of MichiganInorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury | 2026-11-30 |
Add all 33 to your calendar (.ics) → With an account.
Among the 370 studies in Acute Kidney Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Subjects entering the study will have undergone cardiac surgery. Those who experience kidney injury within 48 hours of their surgery will be enrolled into the study. Once enrolled, subjects will receive a single administration of AC607 or placebo. Kidney recovery will be evaluated over the subsequent 30 days and death or the need for dialysis will be evaluated within 90 days of dosing. After 90 days (evaluation period), subjects will enter a 3-year extension phase of the study to monitor safety and long-term outcomes (follow-up period).
The study will enroll post-cardiac surgery subjects (CABG and/or valve) with laboratory evidence of AKI within 48 hrs of removal from cardiopulmonary bypass. Subjects will be randomly assigned (1:1 ratio) to treatment with a single administration of AC607 or placebo (approximately 100 subjects per group).
Safety and efficacy assessments will be performed daily during the post-operative hospital stay from the day randomized into the study until discharge, at 30 days, and at 90 days after study drug administration (evaluation phase). Safety and long-term clinical outcomes will be assessed at 6, 12, 24 and 36 months (long-term follow-up phase).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with AC607
Biological: AC607
Treatment with Placebo
Biological: Vehicle Only
AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight
Also known as: allogeneic bone marrow-derived human mesenchymal, stem cells
The dose will be calculated and recorded in the same way as for AC607.
Time to Kidney Recovery defined as a post-operative serum creatinine return to pre-operative baseline values.
The first occurrence of a post-dosing serum creatinine level that is equal to or less than the subject's pre-operative baseline level.
Time frame: Within 30 days of dosing.
All-Cause Mortality or Dialysis (composite endpoint).
Time frame: Subjects who died or received dialysis within 30 and 90 days after dosing.
The record gives a start of Jun 2012, a primary completion of Jun 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stem Cell
AlloCure Inc.